MAY 13·www.marketscreener.com▼
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is investigating potential claims against ImmunityBio (IBRX) and reminds investors of the May 26, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements about Anktiva's capabilities, specifically that CEO Patrick Soon-Shiong materially overstated them, leading to investor damages. ImmunityBio's stock price fell significantly on January 23, 2026, after the company announced updated Phase 2 clinical results for QUILT 3.078, revealing that the median overall survival, a primary endpoint, had not yet been reached.
MAY 7·The Globe and Mail▼
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit stems from an FDA warning letter issued to ImmunityBio, stating that a TV ad and podcast for their product Anktiva were "false or misleading," leading to a significant drop in ImmunityBio's stock. Investors have until May 26, 2026, to move the court to serve as a lead plaintiff in the case.
